OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
December 20, 2006
Analysts say Times' accusatory articles on Zyprexa are nothing to get excited about.
FDA's revisions to guidelines on expanding access to experimental drugs intensify an already murky issue for pharma.
At its annual pipeline debut, the company introduced its own CETP-inhibitor--with doubts.